Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) ...

A ribbon-cutting ceremony on Oct. 16 marked the formal opening of the new 70,000-square-feet health care hub of White ...